AZ, BioDuro Expand Discovery Pact

BioDuro and AstraZeneca have expanded their discovery research collaboration for respiratory and inflammation indications. BioDuro will provide research services in the areas of discovery chemistry, discovery biology, ADMET, and DMPK services, in an effort to enhance internal drug discovery and shorten development timelines.

“After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics,” said Lena Martensson director of strategic planning and business development.

“BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at AstraZeneca to develop new clinical compounds for respiratory and inflammation indications. This partnership demonstrates the strength of our innovation, quality, and our fully integrated R&D service platform,” commented John Oyler, chief executive officer and co-founder of BioDuro LLC.